| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/18/2011 | US7871613 Adjuvant therapy with the use of anti-glypican 3 antibody |
| 01/18/2011 | US7871612 Using sialoadhesin specific immunoglobulin as diagnostic and/or therapeutic tool in treatment and prevention of allergic, respiratory, cell proliferative and skin disorders |
| 01/18/2011 | US7871611 immunoglobulins; humanizing; chimera; fragments; complementary determining regions; breast cancer |
| 01/18/2011 | US7871610 Antibodies to Tie1 ectodomain |
| 01/18/2011 | US7871606 Use of stimulated peripheral-blood mononuclear cells for the treatment of cancerous diseases |
| 01/18/2011 | US7871604 microbial cells (avirulent Salmonella) comprising Environmentally Limited Viability System; cell is viable in permissive environment and non-viable or temporarily viable in non-permissive environment; antigen for expression of gamete-specific antigens to induce immune responses to block fertility |
| 01/18/2011 | CA2637795C Antagonists of interleukin-15 |
| 01/18/2011 | CA2565925C Vaccine for periodontal disease |
| 01/18/2011 | CA2519408C High concentration antibody and protein formulations |
| 01/18/2011 | CA2394843C A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias |
| 01/18/2011 | CA2383737C Muc-1 derived peptides |
| 01/18/2011 | CA2260858C Polynucleotide vaccine formulation against pathologies of the horse |
| 01/18/2011 | CA2189055C Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 01/13/2011 | WO2011006084A2 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 01/13/2011 | WO2011005850A1 Lipidic compositions for induction of immune tolerance |
| 01/13/2011 | WO2011005799A2 Self replicating rna molecules and uses thereof |
| 01/13/2011 | WO2011005793A1 Cell-based bioprocessing |
| 01/13/2011 | WO2011005715A1 Diagnosis and treatment of autoimmune demyelinating diseases |
| 01/13/2011 | WO2011005613A1 Method for determining if a patient has a traumatic brain injury and related apparatus |
| 01/13/2011 | WO2011005587A1 Vaccine compositions and methods of use to protect against infectious disease |
| 01/13/2011 | WO2011005581A2 Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid |
| 01/13/2011 | WO2011005577A1 Zinc supplementation to increase responsiveness to metalloprotease therapy |
| 01/13/2011 | WO2011005481A1 ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| 01/13/2011 | WO2011005377A2 Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease |
| 01/13/2011 | WO2011005341A2 Compositions and methods related to protein a (spa) variants |
| 01/13/2011 | WO2011005183A1 New composition |
| 01/13/2011 | WO2011004847A1 NOVEL HUMANIZED ANTI-HUMAN α9-INTEGRIN ANTIBODY |
| 01/13/2011 | WO2011004837A1 Antibody having anti-cancer activity |
| 01/13/2011 | WO2011004697A1 Vaccine for crustacean acute viraemia |
| 01/13/2011 | WO2011004552A1 Water-soluble drug carrier and process for production thereof |
| 01/13/2011 | WO2011004146A1 Chimaeric protein |
| 01/13/2011 | WO2011003925A1 Humanised antibodies to toll-like receptor 2 and uses thereof |
| 01/13/2011 | WO2011003920A1 Adjuvated influenza vaccine and use thereof |
| 01/13/2011 | WO2011003809A1 Role of pld1 in thrombus formation and integrin alpha iib beta 3 activation |
| 01/13/2011 | WO2011003780A1 Bi-specific digoxigenin binding antibodies |
| 01/13/2011 | WO2011003557A1 A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent |
| 01/13/2011 | WO2011003369A1 New tumor marker |
| 01/13/2011 | WO2011003138A1 Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| 01/13/2011 | WO2010138839A9 Use of 2 anti-sparc antibodies to predict response to chemotherapy |
| 01/13/2011 | WO2010132697A3 Methods and compositions for treatment |
| 01/13/2011 | WO2010132047A8 Guanosine/gmp gels and uses thereof |
| 01/13/2011 | WO2010129515A8 Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma |
| 01/13/2011 | WO2010102112A9 Treatment of drug-related side effect and tissue damage by targeting the cd24-hmgb1-siglec10 axis |
| 01/13/2011 | WO2010099960A3 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
| 01/13/2011 | WO2010094720A3 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| 01/13/2011 | WO2010037041A3 Frizzled-binding agents and uses thereof |
| 01/13/2011 | WO2010003268A3 Methods and compositions for enhanced delivery of macromolecules |
| 01/13/2011 | US20110010781 Method of Producing a Mouse Suitable for Engraftment, Differentiation and Proliferation of Heterologous Cells, Mouse Produced by This Method and Use of the Mouse |
| 01/13/2011 | US20110010780 Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases |
| 01/13/2011 | US20110009602 Human cd28 specific monoclonal antibodies for antigen-nonspecific activation of t-lymphocytes |
| 01/13/2011 | US20110009570 Preparation of polyphosphazene microspheres |
| 01/13/2011 | US20110009343 Modulators of amyloid aggregation |
| 01/13/2011 | US20110009319 Cripto antagonism of activin and tgf-b signaling |
| 01/13/2011 | US20110009312 Albumin Fusion Proteins |
| 01/13/2011 | US20110008840 Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same |
| 01/13/2011 | US20110008792 Promoters for expression in modified vaccinia virus ankara |
| 01/13/2011 | US20110008452 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 01/13/2011 | US20110008450 Slow Release Compositions |
| 01/13/2011 | US20110008419 Vaccine Against Streptococcus Pneumoniae |
| 01/13/2011 | US20110008418 Compositions and Methods for the Treatment of Cancer |
| 01/13/2011 | US20110008417 Immunomodulating compositions and uses therefor |
| 01/13/2011 | US20110008414 Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines |
| 01/13/2011 | US20110008393 Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer |
| 01/13/2011 | US20110008392 Vaccine targets and delivery systems for cryptosporidium |
| 01/13/2011 | US20110008391 Vaccine composition and immunization method |
| 01/13/2011 | US20110008390 Production of a Viable, Storable Worm Egg Suspension |
| 01/13/2011 | US20110008389 Recombinant attenuated clostridium organisms and vaccine |
| 01/13/2011 | US20110008388 Piglet feed rations having low levels of fermentable carbohydrates |
| 01/13/2011 | US20110008387 Composition containing hcmv particles |
| 01/13/2011 | US20110008386 Use of mva to treat prostate cancer |
| 01/13/2011 | US20110008385 Immunogenic composition |
| 01/13/2011 | US20110008383 Compositions of toll-like receptor agonists and malaria antigens and methods of use |
| 01/13/2011 | US20110008382 Compositions and methods using recombinant MHC molecules for the treatment of uveitis |
| 01/13/2011 | US20110008381 Suppression of allergic inflammation by ascaris heme-binding protein (hbp) |
| 01/13/2011 | US20110008380 Anaplasma Phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma |
| 01/13/2011 | US20110008379 Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| 01/13/2011 | US20110008378 Modified flagellin improved toll-like receptor 5 stimulating activity |
| 01/13/2011 | US20110008377 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides |
| 01/13/2011 | US20110008376 Immunogenic compositions capable of activating t-cells |
| 01/13/2011 | US20110008375 Uses of Myostatin Antagonists |
| 01/13/2011 | US20110008374 Use of IL-1 Antagonists to Treat Gout |
| 01/13/2011 | US20110008373 Prodrugs of cc-1065 analogs |
| 01/13/2011 | US20110008372 Enhancement of light activated drug therapy through combination with other therapeutic agents |
| 01/13/2011 | US20110008371 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 01/13/2011 | US20110008370 Novel use of flj25416 gene |
| 01/13/2011 | US20110008369 Pd-1 binding proteins |
| 01/13/2011 | US20110008368 Methods of modulating the ox40 receptor to treat cancer |
| 01/13/2011 | US20110008367 Anti-vegf antibody |
| 01/13/2011 | US20110008366 Inhibition of versican with sirna and other molecules |
| 01/13/2011 | US20110008365 Methods of treating scleroderma |
| 01/13/2011 | US20110008364 Antibodies to tgf-beta |
| 01/13/2011 | US20110008363 Erythropoietin variants |
| 01/13/2011 | US20110008362 Anti-gluten egg yolk antibodies for the treatment of celiac disease |
| 01/13/2011 | US20110008361 Treatment Method |
| 01/13/2011 | US20110008360 Human antibodies against rabies and uses thereof |
| 01/13/2011 | US20110008359 Monoclonal antibodies against angptl4 |
| 01/13/2011 | US20110008358 Human monoclonal antibodies that specifically bind igf-ii |
| 01/13/2011 | US20110008357 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 01/13/2011 | US20110008356 Il-17 heteromeric receptor complex |
| 01/13/2011 | US20110008355 Anti-flt3 antibodies |